糖尿病
医学
花生四烯酸
内科学
2型糖尿病
内分泌学
脂质代谢
胃肠病学
化学
生物化学
酶
作者
Louise Ménégaut,Aline Laubriet,Valentin Crespy,Maxime Nguyen,Jean‐Michel Petit,Georges Tarris,Thomas Pilot,Alexis Varin,Hélène Choubley,Victoria Bergas,Jean-Paul Paı̈s de Barros,Charles W. Thomas,Éric Steinmetz,David Masson
标识
DOI:10.1016/j.plefa.2022.102477
摘要
Background and aims Diabetes is associated with an accelerated development of atherosclerosis. Specific mechanisms related to diabetes and hyperglycemia may play a role in this process. In particular, alterations of arachidonic acid (AA) metabolism have been reported. Our main goal was to investigate for differences in the concentration of LTB4 and RvD1 as well as selected cyclooxygenase-derived mediators in carotid plaques from diabetic and non-diabetic patients. We also aimed to analyze the relationship between omega 6 and omega 3 Poly-Unsaturated Fatty acids (PUFAs) content in the plaques and the concentrations of these lipid mediators. Methods 29 type 2 diabetic patients and 30 control patients admitted for surgical treatment of carotid stenosis were enrolled in the present study. Carotid plaques were harvested for in-depth lipidomic profiling. Results No differences for LTB4 or other lipid mediators were observed between diabetic and non-diabetic patients. RvD1 levels were below the threshold of quantification in most of the samples. A significant correlation was found between LTB4 and 5(S)-HETE levels. Omega 3 enrichment was not significantly different between control and diabetic plaques. There was a negative correlation between DHA/AA ratio and the level of 5(S)-HETE while there was a positive association with TXB2 and PGD2 concentrations. Conclusion-perspectives Our results does not support the hypothesis of a specific involvement of LTB4 or COX-derived mediators in diabetic atherosclerosis. The relationship between DHA enrichment and the concentrations of specific inflammatory mediators within the plaque is of interest and will need to be confirmed in larger studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI